I don’t think the aim is to provide all permutations in the tool GAJ (ie some permutations may have same outcome) – so much as we be sure that the critical DAA components in each permutation which would produce or require a reframing / diversion in the decision trees are accounted for – Unless in the end, to achieve this, it does require all permutations hope Im making sense archer.

I agree that some variations may (probably will?) give the same outcome.
But using me as an example which past treatment fail should be selected? Interferon/riba or NS3/4/5? I had both in trial but wonder whether the outcome from both choices could be the same? Admittedly mine would be a small subset. And in Tim’s case possibly Inferferon/Riba may be considered close enough?

……..but what about the case of someone who failed Harvoni (branded or generic), should the selection be for failing Sofosbuvir Xwks or failing NS3/4/5? How would that decision be arrived at? And would the outcome be the same for either?

Ouch Tim, that would be 3 jabs per week!